848499-31-0

Basic information

• Product Name: 2-BROMO-THIAZOLE-5-CARBOXAMIDE
• Synonyms: 2-BROMO-THIAZOLE-5-CARBOXAMIDE;2-broMo-1,3-thiazole-5-carboxaMide;2-BroMo-thiazole-4-carboxylic acid aMide;2-Bromo-5-thiazolecarboxamide
• CAS NO: 848499-31-0
• Molecular Formula: C₄H₃BrN₂OS
• Molecular Weight: 207.05
• Mol File: 848499-31-0.mol
• Article Data: 7

Chemical Properties

• Boiling Point: 390.7±15.0 °C(Predicted)
• Appearance: /
• Density: 1.934±0.06 g/cm3(Predicted)
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: 14.38±0.50(Predicted)
• CAS DataBase Reference: 2-BROMO-THIAZOLE-5-CARBOXAMIDE(CAS DataBase Reference)
• NIST Chemistry Reference: 2-BROMO-THIAZOLE-5-CARBOXAMIDE(848499-31-0)
• EPA Substance Registry System: 2-BROMO-THIAZOLE-5-CARBOXAMIDE(848499-31-0)

Safety Data

• Hazardous Substances Data: 848499-31-0(Hazardous Substances Data)

Usage

Uses

2-bromothiazole-5-carboxamide is a useful reactant for the preparation of thiazole analogs as potent stearoyl-CoA desaturase inhibitors.

Upstream product

• 54045-76-0 2-bromo-thiazole-5-carboxylic acid 
• 41731-83-3 ethyl 2-bromo-1,3-thiazole-5-carboxylate 

Downstream Products

• 440100-94-7 2-bromothiazole-5-carbonitrile 
• 1073319-64-8 2-[3-(2-chloro-5-iodophenoxy)propoxy]-1,3-thiazole-5-carboxamide 

Relevant articles and documents

Discovery of potent and liver-targeted stearoyl-CoA desaturase (SCD) inhibitors in a bispyrrolidine series

Inhibition of stearoyl-CoA desaturase (SCD) activity represents a potential novel mechanism for the treatment of metabolic disorders including obesity and type II diabetes. To circumvent skin and eye adverse events observed in rodents with systemically-distributed SCD inhibitors, our research efforts have been focused on the search for new and structurally diverse liver-targeted SCD inhibitors. This work has led to the discovery of novel, potent and structurally diverse liver-targeted bispyrrolidine SCD inhibitors. These compounds possess suitable cellular activity and pharmacokinetic properties to inhibit liver SCD activity in a mouse pharmacodynamic model.

HETEROCYCLIC DERIVATIVES AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE

Heterocyclic compounds of structural formula (I), or a pharmaceutically acceptable salt thereof, wherein W is a R1— substituted heteroaryl, R1 is an heteroaryl ring substituted with an ester or carboxylic acid containing radical, X-T is N—CR5R6, C═CR5 or CR13—CR5R6, Y is a bond or —C(O)—, a and b represent an integer selected from 1 to 4, and Ar is an optionally substituted phenyl or naphtyl, are inhibitors of stearoyl-coenzyme A delta-9 desaturase (SCD) The heterocyclic compounds are useful for the prevention and treatment of conditions related to abnormal lipid synthesis and metabolism, including cardiovascular disease, atherosclerosis, obesity, diabetes, neurological disease, Metabolic Syndrome, insulin resistance, cancer, liver steatosis, and non-alcoholic steatohepatitis.

HETEROCYCLIC DERIVATIVES AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE

Heterocyclic compounds of structural formula (I), or a pharmaceutically acceptable salt thereof, wherein W is a R1-substituted heteroaryl, R1 is an heteroaryl ring substituted with an ester or carboxylic acid containing radical, X-T is N-CR5R6, C=CR5 or CR13-CR5R6, Y is a bond or -C(O)-, a and b represent an integer selected from 1 to 4, and Ar is an optionally substituted phenyl or naphtyl, are inhibitors of stearoyl-coenzyme A delta-9 desaturase (SCD) The heterocyclic compounds are useful for the prevention and treatment of conditions related to abnormal lipid synthesis and metabolism, including cardiovascular disease, atherosclerosis, obesity, diabetes, neurological disease, Metabolic Syndrome, insulin resistance, cancer, liver steatosis, and non-alcoholic steatohepatitis.